Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ganga Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Ganga Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ganga Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ganga Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ganga Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Ganga Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ganga Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ganga Pharmaceuticals (BOM:539680) has a Days Payable of 28.06 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ganga Pharmaceuticals and its competitors. This is 81% below median its historical median of 144.87. Over the past decade, Ganga Pharmaceuticals' Days Payable has ranged from 38.17 to 249.68.
Is Ganga Pharmaceuticals' Days Payable too high?
Ganga Pharmaceuticals' current Days Payable of 28.06 is 81% below median its 10-year median of 144.87. Over the past 10 years, this metric has ranged from a low of 38.17 to a high of 249.68. The Drug Manufacturers industry median Days Payable is 90.38. Ganga Pharmaceuticals' value of 28.06 is 69% below this industry median. Overall, Ganga Pharmaceuticals has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ganga Pharmaceuticals' Days Payable compare to ZTS?
Ganga Pharmaceuticals' Days Payable of 28.06 can be compared against companies in the Drug Manufacturers industry. The industry median Days Payable is 90.38. Ganga Pharmaceuticals' value of 28.06 is 69% below this benchmark. Historically, Ganga Pharmaceuticals' own Days Payable has ranged from 38.17 to 249.68 over the past decade. While the company's 10-year median is 144.87 vs. the industry median of 90.38, Ganga Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ganga Pharmaceuticals's current Days Payable of 28.06 is 69% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ganga Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ganga Pharmaceuticals's current Days Payable is 28.06, which is 81% below median its own 10-year median of 144.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ganga Pharmaceuticals stock overvalued right now?
Ganga Pharmaceuticals (BOM:539680) has a current Days Payable of 28.06. The stock's GF Value™ is ₹11.85, compared to a current price of ₹12.00 — trading 1.3% above its estimated fair value. The current Days Payable is 28.06, which is 81% below median its 10-year median of 144.87 and 69% below the Drug Manufacturers industry median of 90.38. Ganga Pharmaceuticals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ganga Pharmaceuticals (BOM:539680), the current Days Payable is 28.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ganga Pharmaceuticals (BOM:539680) Overvalued in 2026?
Based on GuruFocus' analysis, Ganga Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹12.00 is trading 1.3% above its estimated GF Value™ of ₹11.85.
Key valuation signals for BOM:539680:
Days Payable: 28.06 (81% below median its 10-year median of 144.87)
GF Value™: ₹11.85 vs. price of ₹12.00 (1.3% above fair value)
Industry Position: 69% below the Drug Manufacturers median
No single metric tells the full story. See the BOM:539680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ganga Pharmaceuticals Ltd is an India based producer of ayurvedic medicines. It is engaged in the business of manufacturing and trading in ayurvedic pharmaceuticals and allied products. The company is also involved in the marketing and distribution of bulk ayurvedic medicines. The firm offers ayurvedic medicines for acidity, anti-dandruff, anti-oxidants, dental care, diarrhea, iron tonic, liver disorder, weight management, kidney stone, joint pains, liver disorder and others.
62GF Score
Get the complete analysis for BOM:539680
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539680 has been successfully added to your 
